1.REAL-WORLD EFFECTIVENESS AND SAFETY OF TIXAGEVIMAB-CILGAVIMAB: A TARGET TRIAL EMULATION STUDY

Yan, V, Yang, Y, Wan     More...

Yan, V, Yang, Y, Wan, EYF, Yiu, HHE, Wong, ICK, Chan, EW     Less

VALUE IN HEALTH[1098-3015], Published 2023, Volume 26, Issue 12, Pages S221-S221

收錄情况： WOS

WOS核心合集引用: 0  2023影響因子:  4.9  发表年影響因子:  4.9 

2.PROJECTING COSTS OF CARE BURDEN OF DEPRESSION BETWEEN 2023 AND 2032 IN HONG KONG: A TIMEINHOMOGENEOUS COHORT MARKOV MODEL USING REAL-WORLD EVIDENCE

Chan, V, Leung, MY,     More...

Chan, V, Leung, MY, Yang, D, Knapp, M, Chan, SSM, Luo, H, Craig, D, Chan, EWY, Wong, ICK, Li, X     Less

VALUE IN HEALTH[1098-3015], Published 2023, Volume 26, Issue 12, Pages S87-S88

收錄情况： WOS

WOS核心合集引用: 0  2023影響因子:  4.9  发表年影響因子:  4.9 

3.EARLY INTERVENTION WITH BIOSIMILARS COMPARED WITH LEFLUNOMIDE IN ESTABLISHED RHEUMATOID ARTHRITIS: A COST-EFFECTIVENESS ANALYSIS IN HONG KONG

Peng, K, Chan, SCW,     More...

Peng, K, Chan, SCW, Wang, Y, Cheng, FWT, Yeung, WWY, Jiao, Y, Wong, ICK, Lau, CS, Li, X     Less

VALUE IN HEALTH[1098-3015], Published 2023, Volume 26, Issue 12, Pages S195-S195

收錄情况： WOS

WOS核心合集引用: 0  2023影響因子:  4.9  发表年影響因子:  4.9 

4.COST-EFFECTIVENESS OF POLY ADP-RIBOSE POLYMERASE (PARP) INHIBITORS IN CANCER TREATMENT: A SYSTEMATIC REVIEW

Chan, VKY, Yang, R,     More...

Chan, VKY, Yang, R, Li, Y, Wong, ICK, Li, X     Less

VALUE IN HEALTH[1098-3015], Published 2022, Volume 25, Issue 12, Pages S80-S80

收錄情况： WOS

WOS核心合集引用: 0  2023影響因子:  4.9  发表年影響因子:  4.5 

5.HEALTHCARE RESOURCE UTILIZATION AND COST OF TREATMENT-RESISTANT DEPRESSION: A SIX-YEAR TREND AND COMPARATIVE ANALYSIS IN HONG KONG

Chan, VKY, Cheung, E     More...

Chan, VKY, Cheung, ECL, Chan, SSM, Knapp, M, Lum, TYS, Wan, EYF, Wong, GHY, Chan, EWY, Wong, ICK, Li, X     Less

VALUE IN HEALTH[1098-3015], Published 2022, Volume 25, Issue 12, Pages S53-S53

收錄情况： WOS

WOS核心合集引用: 0  2023影響因子:  4.9  发表年影響因子:  4.5 

6.Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis

Chan, AYL, Chan, VKY     More...

Chan, AYL, Chan, VKY, Olsson, S, Fan, M, Jit, M, Gong, MC, Zhang, SY, Ge, MQ, Pathadka, S, Chung, CCY, Chung, BHY, Chui, CSL, Chan, EW, Wong, GHY, Lum, TY, Wong, ICK, Ip, P, Li, X     Less

VALUE IN HEALTH[1098-3015], Published 2020, Volume 23, Issue 12, Pages 1580-1591

收錄情况： WOS SCOPUS

WOS核心合集引用: 34  2023影響因子:  4.9  发表年影響因子:  5.728 

7.ACCESS AND UNMET NEEDS OF ORPHAN DRUGS IN 194 COUNTRIES AND SIX AREAS: A GLOBAL POLICY REVIEW WITH CONTENT ANALYSIS

Li, SX, Chan, A, Cha     More...

Li, SX, Chan, A, Chan, VKY, Olsson, S, Zhang, S, Fan, M, Jit, M, Gong, MC, Ge, M, Pathadka, S, Chung, CC, Chung, BHY, Chui, CS, Chan, EW, Wong, GH, Lum, TY, Ip, P, Wong, IC     Less

VALUE IN HEALTH[1098-3015], Published 2020, Volume 23, Pages S9-S9

收錄情况： WOS

WOS核心合集引用: 0  2023影響因子:  4.9  发表年影響因子:  5.728 

8.BLEEDING -RELATED HOSPITAL ADMISSIONS AND 30-DAY RE-ADMISSIONS WITH DABIGATRAN VERSUS WARFARIN IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION

Lau, WC, Li, X, Wong     More...

Lau, WC, Li, X, Wong, IC, Chan, EW     Less

VALUE IN HEALTH[1098-3015], Published 2017, Volume 20, Issue 5, Pages A263-A263

收錄情况： WOS

WOS核心合集引用: 0  2023影響因子:  4.9  发表年影響因子:  5.494